Investors were very interested in the Sudeep Pharma initial public offering (IPO) on its second day, which started off with a bang. There is also growing interest in the IPO on the black market, where it is trading at a premium of around Rs. 115, indicating that successful allottees can expect listing gains of almost 19%. The IPO has also gotten a strong subscriptions. By midday on Day 2, the issue had already been oversubscribed by almost three times its total size.
The status of subscriptions for the Sudeep Pharma IPO on Day 2
The IPO for Sudeep Pharma on November 24 was bought out 2.97 times in just two days of bidding. Around 1 p.m., the retail group had the most applications, hitting 3.14 times the number expected. It was subscribed to 6.41 times in the NII segment and only 0.10 times in the QIB segment, excluding anchor investors. This is normal for early bidding days because institutional investors usually join closer to the end date.
Latest Published: Gemini 3 Nano Banana Pro Release
The IPO for Sudeep Pharma is today.
The Sudeep Pharma IPO GMP is trading at Rs. 112 on the uncontrolled dark market as of 10:58 AM on November 24, 2025, which shows that buyers are still interested in the stock before it goes public. The Sudeep Pharma IPO price band is set between Rs. 563 and Rs. 593 per share, so the selling price is likely to be around Rs. 705 per share. This means that buyers who get shares could make a gain of almost 18.89%.
Details on the Sudeep Pharma IPO
The size of the Sudeep Pharma IPO is Rs. 895 crore, which is made up of a fresh issue of Rs. 95 crore and an offer for sale (OFS) by existing owners of Rs. 800 crore. The new money that was raised will be used for working cash needs, business growth, and other general business reasons. This will help the company improve its operational base. Each share is worth Rs. 1, and the price range for them is set at Rs. 563 to Rs. 593 each.
The company raised Rs. 268.50 crore from key investors on November 20, before the issue opened. These investors included local mutual funds and institutional players.
Should you invest in the Sudeep Pharma IPO?
The IPO report from Swastika Investmart gave the Sudeep Pharma IPO a Subscribe grade, which means that they think it will do well. The trading firm said, “The company has strong performance with rising revenues, high EBITDA margins, and an impressive RONW of 27.88% for FY25.” As a chosen partner for important pharmaceutical-grade chemicals, it works with a long list of well-known global clients. The price of the issue is “aggressively priced” at 45–48x P/E, which fully reflects its stable earnings right now. There is not much space for listing gains or short-term pops at this high price. Investors willing to take risks can apply only if they plan to hold the shares for 2 to 5 years.
Sudeep Pharma’s main business plan on Day 2 of the IPO
Grow into high-growth industries: The company is building a factory to make battery-grade iron phosphate (EcoCath) for electric vehicles and energy storage through its partner SAMPL. It will use its infrastructure and eco-friendly processes to make this happen in a way that is sustainable.
Reach a bigger market through a number of business initiatives: Use USFDA-approved skills to grow in controlled markets, reach more customers with Lipoboost liposomal ingredients and Novelcap encapsulated goods, and take advantage of public health efforts led by the government to make a lot of things stronger. About the business
Sudeep Pharma is a technology-driven company that makes unique products and excipients for the food, nutrition, and pharmaceutical businesses. They are committed to making a positive impact on the world’s healthcare system.
In terms of production capacity, the company is one of the biggest that makes food-grade iron phosphate for baby nutrition, clinical nutrition, and the food and drink industries. It is one of the biggest exporters of minerals used in food, medicine, and nutrition.
